bioAffinity Technologies, Inc. Common Stock (BIAF) Stock Price

BIAFStock

$5.19−94.90%52W

Market Cap$2.80M

P/E—

PEG Ratio—

Div yield—

Beta-1.08

BIAF Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-77.51%

Price vs S&P 500 (4W)-41.33%

VGM Score39.85

Book Value / Share (Quarterly)$0.81

P/TBV (Annual)0.81x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.43

Price vs S&P 500 (YTD)-79.08%

Gross Margin (TTM)33.08%

Net Profit Margin (TTM)-280.57%

EPS (TTM)$-11.32

10-Day Avg Trading Volume1.22M

EPS Excl Extra (TTM)$-11.32

EPS (Annual)$-8.66

ROI (Annual)-184.15%

Gross Margin (Annual)31.40%

Cash / Share (Quarterly)$0.69

Revenue Growth QoQ (YoY)-27.09%

ROA (Last FY)-136.03%

Revenue Growth TTM (YoY)-35.75%

EBITD / Share (TTM)$-4.10

Operating Margin (TTM)-204.29%

Cash Flow / Share (Annual)$-2.09

P/B Ratio0.85x

P/B Ratio (Quarterly)4.71x

Net Income / Employee (Annual)$-261,600

EV / Revenue (TTM)0.12x

Net Interest Coverage (TTM)-2.88x

ROA (TTM)-180.44%

EPS Incl Extra (Annual)$-8.66

Current Ratio (Annual)2.60x

Quick Ratio (Quarterly)1.28x

3-Month Avg Trading Volume0.16M

52-Week Price Return-94.90%

Revenue / Employee (TTM)$99,300

Tangible BV / Share (Quarterly)$0.66

P/S Ratio (Annual)0.50x

Asset Turnover (Annual)0.56x

52-Week High$202.50

EPS Excl Extra (Annual)$-8.66

26-Week Price Return-66.26%

Quick Ratio (Annual)2.51x

13-Week Price Return-76.05%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)1.36x

Enterprise Value$699,700

Asset Turnover (TTM)0.64x

Revenue / Employee (Annual)$108,100

Inventory Turnover (Annual)104.16x

Pretax Margin (Annual)-241.25%

Cash / Share (Annual)$1.43

3-Month Return Std Dev109.24%

Net Income / Employee (TTM)$-278,600

ROE (Last FY)-204.87%

Net Interest Coverage (Annual)-2.32x

EPS Basic Excl Extra (Annual)$-8.66

Receivables Turnover (TTM)7.08x

Total Debt / Equity (Quarterly)0.19x

EPS Incl Extra (TTM)$-11.32

Receivables Turnover (Annual)7.57x

ROI (TTM)-163.69%

P/S Ratio (TTM)0.55x

Revenue / Share (Annual)$3.58

Tangible BV / Share (Annual)$1.46

Price vs S&P 500 (52W)-113.21%

Year-to-Date Return-67.12%

5-Day Price Return-18.03%

EPS Normalized (Annual)$-8.66

ROA (5Y Avg)-174.96%

Net Profit Margin (Annual)-241.96%

Month-to-Date Return-38.15%

Cash Flow / Share (TTM)$-0.95

EBITD / Share (Annual)$-5.85

Operating Margin (Annual)-171.58%

LT Debt / Equity (Annual)0.01x

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-11.32

P/TBV (Quarterly)5.82x

P/B Ratio (Annual)0.73x

Inventory Turnover (TTM)64.93x

Pretax Margin (TTM)-279.95%

Book Value / Share (Annual)$1.62

Price vs S&P 500 (13W)-78.84%

Beta-1.08x

Revenue / Share (TTM)$1.26

ROE (TTM)-178.71%

52-Week Low$4.88

vGradeA

gGradeF

mGradeF

vgmGradeD

BIAF Earnings Surprise History

Q4 24-94.50est. -63.00

Q1 25-72.00est. -72.00

Q2 25-76.50est. -45.00

Q3 25-71.10est. -40.50

BIAF Analyst Recommendations

Dec 2025

Jan 2026

Feb 2026

Mar 2026

2.17

Industry Peers — R&D — Physical Sciences(16)

Symbol	Value Score	Growth Score	Momentum Score	Price
BIAFbioAffinity Technologies, Inc. Common Stock	A	F	F	$5.19
IQVIQVIA Holdings Inc.	D	C	A	$259.42
INCYIncyte Genomics Inc	C	A	B	$129.72
MEDPMedpace Holdings, Inc. Common Stock	F	B	A	$614.06
CRLCharles River Laboratories International, Inc.	D	D	A	$297.64
ICLRIcon Plc	C	C	B	$168.91
ABSIAbsci Corporation Common Stock	F	F	A	$9.63
OABIOmniAb, Inc. Common Stock	D	C	A	$4.66
NRCNRC Health Common Stock	D	D	B	$22.02
MXCTMaxCyte, Inc. Common Stock	C	D	B	$1.35
IBACIB Acquisition Corp. Common Stock	—	D	C	$10.89
ONMDOneMedNet Corp Class A Common Stock	D	C	D	$0.59
ISPCiSpecimen Inc. Common Stock	D	F	F	$1.60
BIAFWbioAffinity Technologies, Inc. Warrant	—	—	C	$0.08
NOTVInotiv, Inc. Common Stock	A	B	F	$0.01
OABIWOmniAb, Inc. Warrant	—	—	B	$0.23
ONMDWOneMedNet Corp Warrant	—	—	F	$0.03

About bioAffinity Technologies, Inc. Common Stock

bioAffinity Technologies Inc develops noninvasive diagnostic tests and targeted cancer therapeutics, with a focus on early-stage cancer detection. The company's lead product, CyPath Lung, is a proprietary noninvasive test for detecting early-stage lung cancer. Its technology platform addresses a significant clinical market need for improved cancer diagnosis and treatment options.